ABSTRACT Aims This prespecified analysis evaluated whether the safety and efficacy of finerenone and a sodium–glucose cotransporter 2 inhibitor (SGLT2i) combination vary by baseline glycated haemoglobin (HbA1c). Materials and Methods Adults with type 2 diabetes and a urinary albumin‐to‐creatinine ratio (UACR) of 100 − 6.4 and ≤ 7.1% > 46 and ≤ 54 mmol/mol), 3 (HbA1c > 7.1 and ≤ 7.9% > 54 and ≤ 63 mmol/mol) and 4 (HbA1c > 7.9% > 63 mmol/mol), respectively. Change from baseline in HbA1c at Day 180 was greatest in Quartile 4. At Day 180, combination therapy reduced UACR from baseline in all HbA1c quartiles to a greater extent than either monotherapy (mean 95% CI –53% −63, −42, −47% −57, −34, −63% −70, −54 and −55% −65, −42, in Quartiles 1–4, respectively). Conclusion Simultaneous initiation with finerenone and an SGLT2i reduced UACR compared with monotherapy and was well‐tolerated irrespective of HbA1c levels.
McGill et al. (Mon,) studied this question.